What alternatives are available for a patient with type 2 diabetes who is not covered by Medicare for Farxiga (dapagliflozin) and GLP-1 (Glucagon-Like Peptide-1) receptor agonists?

Alternative Glucose-Lowering Agents When SGLT2 Inhibitors and GLP-1 Receptor Agonists Are Not Covered

When Farxiga (dapagliflozin) and GLP-1 receptor agonists are not covered by Medicare, metformin combined with a DPP-4 inhibitor (such as sitagliptin or linagliptin) represents the most appropriate alternative, as these agents provide effective glycemic control with minimal hypoglycemia risk and neutral effects on cardiovascular outcomes, though they lack the mortality and cardiovascular benefits of the preferred agents. 1

First-Line Foundation Therapy

• Metformin remains the cornerstone of type 2 diabetes management and should be continued or initiated if not already prescribed, as it is recommended by all major guidelines as the preferred initial agent 1, 2
• Metformin can be used at doses up to 2,000-2,550 mg daily, with generic formulations costing as little as $2-3 per month for immediate-release preparations 1
• Metformin should be avoided only if eGFR is <30 mL/min/1.73 m² 1

Second-Line Options: DPP-4 Inhibitors as Primary Alternative

DPP-4 inhibitors represent the most suitable alternative when SGLT2 inhibitors and GLP-1 receptor agonists are unavailable, as they provide:

• HbA1c reduction of approximately 0.7-1.0% when added to metformin 1
• Neutral cardiovascular effects without increasing heart failure risk (except saxagliptin, which should be avoided) 1
• Minimal hypoglycemia risk when used without sulfonylureas or insulin 1
• Weight neutrality without the weight gain seen with insulin or sulfonylureas 3

Specific DPP-4 Inhibitor Selection:

• Sitagliptin 100 mg daily or linagliptin 5 mg daily are preferred agents, as they have demonstrated no increased heart failure signal 1
• Avoid saxagliptin, as it is specifically not recommended in patients with high risk of heart failure 1
• Monthly costs range from $444-568 for brand-name preparations, though generic options may become available 1

Third-Line Considerations: Sulfonylureas

If cost is the primary barrier and DPP-4 inhibitors remain unaffordable:

• Second-generation sulfonylureas (glimepiride, glipizide, or glyburide) provide effective glucose lowering at very low cost ($4-11 per month for generic formulations) 1
• Major limitation: increased hypoglycemia risk, particularly in elderly patients or those with irregular meal patterns 1
• Weight gain of 2-3 kg is expected 1
• Use the lowest effective dose and educate patients extensively about hypoglycemia recognition and management 1

Insulin as Last Resort

When oral agents fail to achieve glycemic targets:

• Basal insulin (NPH or long-acting analogs) can be added to metformin 1
• Critical disadvantage: increased hypoglycemia risk and weight gain compared to SGLT2 inhibitors and GLP-1 receptor agonists 1
• Mortality outcomes are inferior to SGLT2 inhibitors and GLP-1 receptor agonists in comparative trials 1
• Consider insulin only when oral combinations are insufficient and the preferred agents remain inaccessible 1

Agents to Avoid

• Thiazolidinediones (pioglitazone) are contraindicated in patients with any history of heart failure and increase heart failure risk even in those without established disease 1
• Saxagliptin should not be used in patients at high risk for heart failure 1

Critical Caveat: Cardiovascular and Renal Protection

The most important limitation of these alternatives is the absence of proven mortality and cardiovascular benefits:

• SGLT2 inhibitors and GLP-1 receptor agonists reduce all-cause mortality and major adverse cardiovascular events, while DPP-4 inhibitors, insulin, and sulfonylureas do not 1
• SGLT2 inhibitors specifically reduce heart failure hospitalizations and chronic kidney disease progression, benefits not seen with alternative agents 1
• For patients with established cardiovascular disease, heart failure, or chronic kidney disease, aggressive advocacy for coverage of SGLT2 inhibitors or GLP-1 receptor agonists is warranted, as these patients derive the greatest benefit from these agents 1, 4

Practical Implementation Algorithm

1. Ensure metformin is optimized (maximum tolerated dose up to 2,000-2,550 mg daily) 1
2. Add sitagliptin or linagliptin as second-line therapy for additional HbA1c reduction of 0.7-1.0% 1
3. If cost prohibitive, consider generic sulfonylurea (glimepiride 1-8 mg daily or glipizide 5-40 mg daily) with extensive patient education about hypoglycemia 1
4. Reserve basal insulin for patients who fail oral combination therapy 1
5. Continuously advocate for coverage of SGLT2 inhibitors or GLP-1 receptor agonists, particularly in patients with cardiovascular disease, heart failure, or chronic kidney disease 1, 4